<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28225969</article-id>
      <article-id pub-id-type="pmc">5312191</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20174871</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Exuberant pyoderma gangrenosum in a patient with autoimmune
hepatitis<xref ref-type="fn" rid="fn1">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dantas</surname>
            <given-names>Stephanie Galiza</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Quintella</surname>
            <given-names>Leonardo Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Nurimar Concei&#xE7;&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Dermatology of the Universidade Federal do
Rio de Janeiro (UFRJ) - Rio de Janeiro (RJ), Brazil</aff>
      <aff id="aff2"><label>2</label>Department of Pathology of the Funda&#xE7;&#xE3;o
Oswaldo Cruz (Fiocruz) - Rio de Janeiro (RJ), Brazil</aff>
      <author-notes>
        <corresp id="c1">Mailing address: Stephanie Galiza Dantas, Rua Rodolpho Paulo Rocco,
255, 5&#xBA; andar, Secretaria de Dermatologia, Cidade Universit&#xE1;ria, Ilha do
Fund&#xE3;o, 21941-913 - Rio de Janeiro, RJ Brazil. E-mail:
<email>stegaliza@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Feb</season>
        <year>2017</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2017</year>
      </pub-date>
      <volume>92</volume>
      <issue>1</issue>
      <fpage>114</fpage>
      <lpage>117</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>1</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2017 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2017</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Pyoderma gangrenosum is a rare neutrophilic dermatosis, which usually presents as
ulcers with erythematous-violaceous undermined edges and a rough base with
purulent or sanguinous exudate. It can be primary or associated with an
underlying disease. However, rare cases of its association with autoimmune
hepatitis have been described in the literature. Diagnosis is based on a
characteristic clinical picture and ruling out other causes of ulcers. This
paper aims to discuss the management of corticosteroid therapy and the
importance of local treatment. We report a case with torpid evolution, presented
with multiple and deep ulcers in a young patient with autoimmune hepatitis,
causing pain and significant disability. We observed complete healing of lesions
after two months of successful treatment.</p>
      </abstract>
      <kwd-group>
        <kwd>Autoimmune hepatitis</kwd>
        <kwd>Hepatitis</kwd>
        <kwd>Leg ulcer</kwd>
        <kwd>Pyoderma</kwd>
        <kwd>Pyoderma gangrenosum</kwd>
        <kwd>Sodium carboxymethylcellulose</kwd>
        <kwd>Skin Ulcer</kwd>
        <kwd>Therapeutics</kwd>
        <kwd>Ulcer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis, with an estimated annual
incidence of 3-10 cases per million in the population.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> It can present itself as a primary disorder or be
associated with an underlying disease, particularly inflammatory bowel disease
(IBD), arthritis, hematologic diseases, and malignant diseases.<sup><xref rid="r2" ref-type="bibr">2</xref></sup></p>
      <p>Typical clinical presentation consists of a pustule or nodule that evolves into a
painful ulcer with an undermined and well-defined erythematous-violaceous border.
The base of the ulcer commonly has granulation tissue with purulent or sanguinous
exudate. It is usually located on lower limbs and displays centrifugal growth. Other
possible forms of presentation include vegetative, bullous, and pustular types.</p>
      <p>Its frequent association with autoimmune diseases and pathergy corroborate the
hypothesis of PG as an autoimmune disease.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Pathergy, which occurs in about 30% of cases, consists of
the appearance of new lesions or the worsening of pre-existing lesions after a local
trauma.<sup><xref rid="r4" ref-type="bibr">4</xref></sup></p>
      <p>The diagnosis is made - in addition to its compatible clinical characteristics - by
excluding other causes of similar-appearing cutaneous ulcerations - including
infection, malignancy, and vasculitis - by histopathological examination and
laboratory study.</p>
      <p>The treatment of secondary PG should consider the treatment of the underlying
disease. In primary PG, corticosteroid therapy is the gold standard, sometimes in
combination with immunosuppressant therapy.<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p>
      <p>This paper aims to discuss an exuberant case of PG in a young patient with autoimmune
hepatitis (AIH), emphasizing corticosteroid therapy management and the importance of
local treatment.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>We report a 25-year-old female patient with recurrent ulcers on the lower limbs for
the past four years. She reported onset with pustules, which progressed to
ulceration in the left medial malleolus region. Later, she noticed other similar
ulcers on both lower limbs, with disabling local pain. As a relevant medical record,
she had type 1 AIH. She was on prednisone (20 mg daily) and azathioprine (100 mg
daily) - precribed for AIH - and clobetasol cream 0.05%.</p>
      <p>Physical examination revealed a deep ulcerated lesion on the lateral side of the
right lower limb (RLL), about 5 cm in diameter, reaching the subcutaneous tissue,
with violaceous regular and undermined edges, and base with purulent exudate and
granulation tissue. We also observed two other ulcerated lesions on the lateral side
of the RLL and an ulcer on the medial side of the RLL with similar characteristics
(<xref ref-type="fig" rid="f1">Figure 1</xref>). Similar ulcers were observed in
the anterior aspect of the left lower limb (LLL) and the medial aspect of the LLL -
the latter particularly deep, with maceration on the edges and smaller adjacent
ulceration. A total of seven ulcers were observed (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Right lower limb: aspect before treatment. Three deep ulcers on the
lateral aspect and an ulcer in the medial region of the limb reaching
the subcutaneous tissue, with violaceous regular and undermined
edges</p>
          </caption>
          <graphic xlink:href="abd-92-01-0114-gf01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Left lower limb: aspect before treatment. On the left, deep ulcer with
violaceous irregular and macerated edges in left medial malleolus
region, with smaller adjacent ulceration. On the right, ulcer on the
anteromedial aspect of the limb. We also observed atrophic scars caused
by previous ulcers.</p>
          </caption>
          <graphic xlink:href="abd-92-01-0114-gf02"/>
        </fig>
      </p>
      <p>Histopathological study of a lesion revealed unspecific, ulcerated, and chronic
inflammation process (<xref ref-type="fig" rid="f3">Figures 3</xref> and <xref ref-type="fig" rid="f4">4</xref>). The search for mycobacteria, fungi, and
sporotrichosis serology were negative. PCR for leishmaniasis and leishmanin skin
test were also negative. Laboratory tests revealed elevated C-reactive protein,
glucose intolerance, and normal liver laboratory tests, except for the elevation of
gamma-glutamyltransferase.</p>
      <p>
        <fig id="f3" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Histopathology. Ulcerated area with granulation tissue, recent
hemorrhage, perivascular mononuclear inflammatory infiltrate and
fibrosis (Hematoxylin &amp; eosin x40)</p>
          </caption>
          <graphic xlink:href="abd-92-01-0114-gf03"/>
        </fig>
      </p>
      <p>
        <fig id="f4" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Histopathology. Histological detail showing inflammatory infiltrate
composed of lymphocytes arranged around vessels (Hematoxylin &amp; eosin
x100)</p>
          </caption>
          <graphic xlink:href="abd-92-01-0114-gf04"/>
        </fig>
      </p>
      <p>We started treatment with prednisone at a dose of 70 mg/daily (1 mg/kg/day). In the
first week, we used dressings with silver sulfadiazine 1% on the lesions. From the
second week, we used dressings with carboxymethyl cellulose 3% gel and Nystatin
ointment with zinc oxide - the latter only on the macerated edge of the ulcer in the
left medial malleolus region (candidiasis associated). We recommended resting and
keeping the lower limbs elevated.</p>
      <p>The patient was discharged after 18 days of hospitalization, with the prescription of
prednisone (60 mg/daily) and daily dressings as described above, as well as guidance
to rest and elevate the lower limbs. Initially, we programmed the reduction of
Prednisone by 10 mg per month. The patient returned a month after discharge showing
healing process in the ulcers (<xref ref-type="fig" rid="f5">Figure 5</xref>). Two
months after discharge, the seven ulcers were completely resolved with use of
prednisone 40 mg/daily. Three months after discharge, we still observed the complete
healing of ulcers with prednisone 30 mg/daily and emollient. At the time, we reduced
the prednisone dose to 20 mg/daily and kept emollient topical care (<xref ref-type="fig" rid="f6">Figure 6</xref>).</p>
      <p>
        <fig id="f5" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <p>One month after the initiation of treatment. Healing ulcers on the right
(A) and left (B) lower limbs. Re-epithelialization occurs from the edges
of the lesion</p>
          </caption>
          <graphic xlink:href="abd-92-01-0114-gf05"/>
        </fig>
      </p>
      <p>
        <fig id="f6" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Three months after initiation of treatment. Complete healing of ulcers on
the lateral aspect of the right lower limb</p>
          </caption>
          <graphic xlink:href="abd-92-01-0114-gf06"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Pyoderma gangrenosum (PG) is a rare dermatosis, and its association with autoimmune
hepatitis (AIH) was rarely described in the literature. We report a case with torpid
evolution, presenting with multiple and deep ulcers in a young patient with
autoimmune hepatitis, causing pain and significant disability. Although the patient
was treated with prednisone and azathioprine - both prescribed for AIH - the lesions
showed no clinical improvement. In the present case, PG and the underlying disease
did not follow parallel clinical courses, since AIH was inactive. It is known that
the course of the PG can be parallel or not parallel in cases associated with
underlying IBD.<sup><xref rid="r6" ref-type="bibr">6</xref></sup></p>
      <p>The systemic corticosteroid therapy is the treatment of choice for PG. High initial
doses are often necessary, such as prednisone 60-80 mg/daily.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> In the present case, we initially
prescribed prednisone 1 mg/kg/daily, an equivalent to 70 mg/daily. There are reports
on the successful use of azathioprine for PG treatment, but they still require
further scientific evidence.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> We
believe that the importance given to local treatment was essential for the healing
of the lesions. In this particular case, we applied silver sulfadiazine topical 1%,
given the large amount of purulent exudate. Although it may be sterile in PG, we
suspected secondary infection, considering the recent worsening of the lesion and
the increased pain reported by the patient. Then we used carboxymethyl cellulose gel
3%, one of the components of the hydrogel dressing, which has healing properties by
aiding cell rehydration and autolytic debridement.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> Because of the high cost of commercial hydrogel
dressing, we chose to use isolated carboxymethyl cellulose.</p>
      <p>We further emphasize the slow withdrawal of corticosteroid therapy: after 17 days
using 1 mg/kg/daily, given the evolutionary improvement observed, we started to
reduce by 10 mg every month; after 30 mg/daily, we reduced 10 mg every 15 days. We
highlight the surprisingly satisfactory response to treatment, with complete healing
of the lesions within two months. Currently, the patient is on prednisone 20
mg/daily without remission. However, long-term follow up is necessary, given the
variable course of PG.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None.</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work performed at Hospital Universit&#xE1;rio Clementino Fraga Filho - Rio de
Janeiro (RJ), Brazil.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahronowitz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Harp</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shinkai</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Etiology and management of pyoderma gangrenosum: a comprehensive
review</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>191</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="pmid">22356259</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Konopka</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Padulla</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Ortiz</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Bittencourt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dalcin</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Pioderma Gangrenoso: um Artigo de Revis&#xE3;o</article-title>
          <source>J Vasc Bras</source>
          <year>2013</year>
          <volume>12</volume>
          <fpage>25</fpage>
          <lpage>33</lpage>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coors</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>von den Driesch</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Pyoderma gangrenosum in a patient with autoimmunehaemolytic
anaemia and complement deficiency</article-title>
          <source>Br J Dermatol</source>
          <year>2000</year>
          <volume>143</volume>
          <fpage>154</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">10886151</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonamigo</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Razera</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Silveira</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Dermatoses neutrof&#xED;licas - Parte I</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>11</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">21437518</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reichrath</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bens</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bonowitz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tilgen</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Treatment recommendations for pyoderma gangrenosum: an
evidence-based review of the literature based on more than 350
patients</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2005</year>
          <volume>53</volume>
          <fpage>273</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="pmid">16021123</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruocco</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sangiuliano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gravina</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nicoletti</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Pyoderma gangrenosum: an updated review</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2009</year>
          <volume>23</volume>
          <fpage>1008</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">19470075</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bolognia</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Jorizzo</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Rapini</surname>
              <given-names>RP</given-names>
            </name>
          </person-group>
          <source>Pyoderma gangrenosum: Dermatology</source>
          <year>2003</year>
          <volume>1</volume>
          <fpage>415</fpage>
          <lpage>418</lpage>
          <publisher-loc>London</publisher-loc>
          <publisher-name>Mosby</publisher-name>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Berth-Jones</surname>
            </name>
          </person-group>
          <source>Treatament of Skin Disease - comprehensive therapeutic
strategies</source>
          <chapter-title>Pyoderma gangrenosum</chapter-title>
          <year>2006</year>
          <edition>2nd ed</edition>
          <publisher-loc>Lippincott Williams &amp; Wilkins</publisher-loc>
          <publisher-name>Philadelphia</publisher-name>
          <fpage>560</fpage>
          <lpage>564</lpage>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franco</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Feridas cut&#xE2;neas: a escolha do curativo
adequado</article-title>
          <source>Rev Col Bras Cir</source>
          <year>2008</year>
          <volume>35</volume>
          <fpage>203</fpage>
          <lpage>206</lpage>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Binus</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Qureshi</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>VW</given-names>
            </name>
            <name>
              <surname>Winterfield</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
          <article-title>Pyoderma gangrenosum: a retrospective review of patient
characteristics, comorbidities, and therapy in 103 patients</article-title>
          <source>Br J Dermatol</source>
          <year>2011</year>
          <month>12</month>
          <volume>165</volume>
          <fpage>1244</fpage>
          <lpage>1250</lpage>
          <pub-id pub-id-type="pmid">21824126</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
